Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04697888 · ClinicalTrials.gov registry record · Phase 2
Use of Omegaven for Treatment With Parenteral Nutrition Associated Liver Disease
A Phase 2 study of Parenteral Nutrition-related Hepatitis, sponsored by Children's Mercy Hospital Kansas City.
- Completed
- Registry status
- Phase 2
- Development phase
- 2
- Enrollment target
- 1
- Study location
NCT04697888 is a Phase 2 study of Parenteral Nutrition-related Hepatitis that has completed, run by Children's Mercy Hospital Kansas City. The registered enrollment target is 2 participants. The trial reports 1 study location across 1 state.
The verdict
NCT04697888, a Phase 2 study of Parenteral Nutrition-related Hepatitis, has completed, sponsored by Children's Mercy Hospital Kansas City.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 2 participants
- Enrollment target
- 1
- Study location
Study Summary
To provide parenteral fat emulsion prepared from fish oil (omega-3 fatty acid emulsion, Omegaven®) to patients with liver disease (PNALD).
Conditions Studied
Interventions
- DRUG Omegaven
Study Locations (1)
Missouri
- Children's Mercy Hospitals and Clinics - Kansas City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2013-04 |
| Est. Completion | 2018-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04697888
The ClinicalTrials.gov registry entry for NCT04697888 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Children's Mercy Hospital Kansas City, which has 184 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Parenteral Nutrition-related Hepatitis appearing as the primary indexed condition, and to 1 intervention - of which Omegaven is the first listed.
NCT04697888 reports 1 study location spanning 1 distinct geographic area - top geographies include Missouri.
Frequently Asked Questions
What is clinical trial NCT04697888 about?
NCT04697888 is a clinical study titled "Use of Omegaven for Treatment With Parenteral Nutrition Associated Liver Disease". To provide parenteral fat emulsion prepared from fish oil (omega-3 fatty acid emulsion, Omegaven®) to patients with liver disease (PNALD).
What is the current status of trial NCT04697888?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2013-04. Estimated completion is 2018-11.
What conditions does trial NCT04697888 study?
This clinical trial studies the following conditions: Parenteral Nutrition-related Hepatitis.
What interventions are being tested in trial NCT04697888?
The interventions under investigation include: Omegaven (DRUG).
Who is sponsoring clinical trial NCT04697888?
This trial is sponsored by Children's Mercy Hospital Kansas City, which has 184 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04697888 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.